Breaking News

Scimega, Q-CROC in Biomarkers Research Alliance

By Kristin Brooks | December 12, 2013

Will work to identify predictive biomarkers in drug-resistant tumors

Scimega Research has been selected by the Quebec – Clinical Research Organization in Cancer (Q-CROC) to oversee the conduct of three studies to identify predictive biomarkers in drug-resistant tumors.
In February 2013, the Minister of Finance and the Economy, and the Minister for Industrial Policy, and the Quebec Economic Development Bank, Élaine Zakaïb, invested $10 million in the Personalized Medicine Partnership for Cancer (PMPC), a public-private partnership for implementation of personalized medicine in cancer. The PMPC will be supported by the Q-CROC’s hospital and university network, which currently has members in 15 healthcare establishments and 16 research centers in the province.
“Personalized medicine represents a paradigm shift for the key stakeholders involved in cancer drug development. Collectively, we all have an important role to play in the fight against cancer and this is an excellent example of a unifying partnership that brings us one step closer to making personalized medicine a reality, and patient-centered treatment, a standard,” said Denise Deakin, president and co-founder of Scimega Research.

Related Contract Manufacturing:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent